Navigation Links
NeuroPhage to Participate in World's First G8 Dementia Summit

CAMBRIDGE, Mass., Dec. 3, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been invited to participate in the world's first G8 Dementia Summit. The G8 Summit is hosted by the British Prime Minister, David Cameron, and Health Secretary, Jeremy Hunt, and will be attended by G8 Health Ministers, pharmaceutical company leaders, innovators, technology pioneers, breakthrough researchers and investors. The Summit will explore the coordination of efforts to shape an effective international solution to dementia, a condition that affects over 35 million people worldwide, including looking for effective therapies to slow dementia's impact. The G8 Dementia Summit will take place in London, UK, on December 11, 2013.

"We applaud this groundbreaking initiative that the Prime Minister and the Health Secretary have undertaken to bring together leaders from government, research and finance to focus on addressing the enormous health and economic burden that dementia has on patients and families around the world," said Jonathan Solomon, President and Chief Executive Officer of NeuroPhage. "Dementia has proved to be a challenging indication to treat, as the biology behind the various conditions is complex. We are honored to take part in this ambitious international effort in hopes to create a greater collaborative approach worldwide to better achieve our common goals of treating and preventing dementia."

About NeuroPhage  

NeuroPhage Pharmaceuticals has fusion-protein drug candidates in development for neurodegenerative diseases, many of which cause progressive mental deterioration and dementia.  NeuroPhage's technology is based on a General Amyloid Interaction Motif (GAIM) that simultaneously targets multiple misfolded proteins or amyloids central to many neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. In addition to targeting multiple misfolded pathological proteins, this unique disease-modifying approach recognizes early amyloid assemblies and existing protein aggregates to maximize potential therapeutic effect. NeuroPhage is initially developing candidates to treat Alzheimer's and Parkinson's disease, where a number of different misfolded proteins are present and their interactions can exacerbate disease progression.

SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
2. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
3. Hill-Rom to Participate in the 25th Annual Piper Jaffray Healthcare Conference
4. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
5. Boston Scientific To Participate In 2013 Credit Suisse Healthcare Conference
6. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
7. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
8. montmed to participate in Vascular 2013
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Amgen To Participate At Citis 8th Annual Biotech Conference
11. China Biologic to Participate in Upcoming Investor Conferences
Post Your Comments:
(Date:11/27/2015)... DUBLIN , Nov. 26, 2015 /PRNewswire/ ... announced the addition of the "2016 ... by Test, Country Volume and Sales Segment ... Emerging Opportunities" report to their offering. ... the addition of the "2016 Global ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings ... with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired ... font, giving users limitless opportunities to stylize and create designs quickly and easily, ...
Breaking Medicine News(10 mins):